Syndax Pharmaceuticals

SNDX Rare disease Lead: Approved 1 Biotech Distilled article ↓

Most recent annual filing: 2026-02-26

Catalyst timeline

Revuforj 2H26 revumenib readout2H 2026Revuforj 2H26 revumenib readout, 2H 2026, notable
SNDX-4321 EGFR IND filingYE 2026SNDX-4321 EGFR IND filing, YE 2026, notable
Revuforj revumenib Ph2 start~YE 2026Revuforj revumenib Ph2 start, ~YE 2026, routine
Revuforj 4Q26 revumenib readout4Q 2026Revuforj 4Q26 revumenib readout, 4Q 2026, material
Niktimvo MAXPIRe axatilimab Ph2 readout4Q 2026Niktimvo MAXPIRe axatilimab Ph2 readout, 4Q 2026, notable
Niktimvo cGVHD axatilimab Ph2 readout4Q 2026Niktimvo cGVHD axatilimab Ph2 readout, 4Q 2026, notable
Revuforj revumenib trial start4Q 2026Revuforj revumenib trial start, 4Q 2026, routine
SNDX-62122 next-gen menin Ph1 start2027SNDX-62122 next-gen menin Ph1 start, 2027, routine
SNDX-4321 EGFR Ph1 start2027SNDX-4321 EGFR Ph1 start, 2027, routine
Revuforj 2H27 revumenib readout2H 2027Revuforj 2H27 revumenib readout, 2H 2027, material
Niktimvo axatilimab Ph3 readoutEarly 2028Niktimvo axatilimab Ph3 readout, Early 2028, notable
SNDX-4321 EGFR readoutearly 2028SNDX-4321 EGFR readout, early 2028, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Revuforj

revumenib

Small Molecule Target: menin, menin-KMT2A, KMT2A, NPM1, Menin

Relapsed/Refractory Acute Leukemia with KMT2A Translocation Approved oral NCT04065399
Relapsed/Refractory Acute Myeloid Leukemia with NPM1 Mutation Approved oral NCT03013998
Myelofibrosis Preclinical Phase 1/2 trial oral NCT07734077
Metastatic Colorectal Cancer Phase 1

Niktimvo

axatilimab-csfr · axatilimab · UCB6352

Protein Target: CSF-1R, CSF1R

Chronic Graft-Versus-Host Disease Approved Incyte NCT03604692
Idiopathic Pulmonary Fibrosis Phase 2 Incyte NCT06132256

SNDX-4321

Small Molecule Target: EGFR

Non-Small Cell Lung Cancer Preclinical Dana-Farber Cancer Institute

SNDX-62122

Small Molecule Target: menin

Myelofibrosis Preclinical

Discontinued (2)

Revuforj — Colorectal Cancer · Limited anti-tumor efficacy observed; no patients achieved clinical response; company decided not to pursue further development in CRC
entinostat — undisclosed · Deprioritized. 10-K 2026-02-26: "We have deprioritized the development of entinostat, but maintain a license, development and commercialization agreement ... with Eddingpharm" to commercialize it in China and certain other Asian countries. Syndax also recorded a full reserve against the $3.7M Eddingpharm milestone receivable, assessed as non-recoverable.

Biotech Distilled coverage (1)

2026-09-04 Syndax Pharmaceuticals (SNDX) - Scientific Deep Dive for Revuforj, Niktimvo and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.